Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,293,786 papers from all fields of science
Search
Sign In
Create Free Account
1 ML secukinumab 150 MG/ML Prefilled Syringe [Cosentyx]
Known as:
Cosentyx 150 MG/ML 1ML Prefilled Syringe
, SECUKINUMAB 150 mg in 1 mL SUBCUTANEOUS INJECTION [COSENTYX]_#2
, 1 ML Cosentyx 150 MG/ML Prefilled Syringe
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
12 relations
1 ML secukinumab 150 MG/ML Auto-Injector [Cosentyx]
Cosentyx
HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE
Histidine
Expand
Broader (2)
1 ML secukinumab 150 MG/ML Prefilled Syringe
Cosentyx Injectable Product
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Interleukin-17A-Inhibitor bei axialer Psoriasis-Arthritis wirksam
Sabine Jost
Der Deutsche Dermatologe
2019
Corpus ID: 201848969
Mit dem Interleukin(IL)-17A-Inhibitor Secukinumab (Cosentyx®) wurde erstmals ein Biologikum bei axial ausgeprägter…
Expand
2019
2019
Severe colitis complicating secukinumab (Cosentyx®) therapy
A. S. W. Lee
,
N. Levell
,
S. N. Shah
,
K. Gaffney
,
M. Tremelling
Clincal and Experimental Dermatology
2019
Corpus ID: 209418052
of acute myelogenous leukaemia (AML) was evaluated by the dermatology department because of a 1-month history of progressive…
Expand
2018
2018
THU0319 Overall safety of 7-week secukinumab exposure during pregnancy in women with psoriatic arthritis
M. S. Ferreira
,
Ricardo Machado Xavier
,
+10 authors
P. Palominos
THURSDAY, 14 JUNE :
2018
Corpus ID: 80807778
Background Psoriatic arthritis (PsA) often affects women of reproductive age. Secukinumab (SEC), a monoclonal antibody against…
Expand
2018
2018
Clinical outcomes in patients on secukinumab (Cosentyx®) within a specialist psoriasis clinic: a single centre, retrospective cohort study
A. V. Sears
,
A. V. Sears
,
+7 authors
A. E. Pink
Journal of the European Academy of Dermatology…
2018
Corpus ID: 52177545
Secukinumab, a fully human anti-IL-17A monoclonal antibody, is a highly effective therapy for chronic plaque psoriasis. Up to 81…
Expand
Review
2017
Review
2017
Secukinumab (Cosentyx°) and plaque psoriasis.
Prescrire international
2017
Corpus ID: 73417787
2016
2016
Aknetherapie: Vorteile durch innovative Fixkombination
Springer Medizin
hautnah dermatologie
2016
Corpus ID: 190185131
— „Psoriasis kann als Prototyp einer chronisch-entzündlichen Erkrankung angesehen werden“, konstatierte Prof. Georg Schett…
Expand
2015
2015
Cost-effectiveness of secukinumab (Cosentyx®) for the treatment of moderate to severe plaque psoriasis The NCPE has issued a recommendation regarding the cost-effectiveness of secukinumab (Cosentyx…
2015
Corpus ID: 7027859
The HSE asked the National Centre for Pharmacoeconomics (NCPE) to carry out an assessment of the applicant’s (Novartis Ireland…
Expand
Review
2015
Review
2015
Profile of secukinumab in the treatment of psoriasis: current perspectives
Michael Roman
,
V. Madkan
,
M. Chiu
Therapeutics and Clinical Risk Management
2015
Corpus ID: 4533000
Secukinumab (Cosentyx™) is a human monoclonal IgG1k antibody that has been developed to target and block the actions of IL-17A…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE